Acute Myeloid Leukemia, Adult

Oncology
3
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
DECITABINEApproved
decitabine
Unknown Company
Nucleoside Metabolic Inhibitor [EPC]intravenous2020

Competitive Landscape

3 companies ranked by most advanced pipeline stage

City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
DecitabinePhase 31 trial
Active Trials
NCT02985372UnknownEst. Dec 2019
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
FludarabinePhase 21 trial
Active Trials
NCT04425655Terminated2Est. Jul 2022
Fresenius Kabi
Fresenius KabiGermany - Bad Homburg
1 program
Experimental groupN/A1 trial
Active Trials
NCT04240600Unknown74Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
City TherapeuticsDecitabine
Jazz PharmaceuticalsFludarabine
Fresenius KabiExperimental group

Clinical Trials (3)

Total enrollment: 76 patients across 3 trials

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Start: Dec 2016Est. completion: Dec 2019
Phase 3Unknown

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Start: Aug 2020Est. completion: Jul 20222 patients
Phase 2Terminated
NCT04240600Fresenius KabiExperimental group

Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay

Start: Dec 2020Est. completion: Dec 202174 patients
N/AUnknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space